Quantcast
Last updated on April 21, 2014 at 7:52 EDT

Latest Nerve growth factor Stories

2013-11-15 08:27:03

Data Demonstrate Long-Term Expression of Functional Nerve Growth Factor in the Brain and Stabilization of Brain Cell Metabolic Activity RICHMOND, Calif., Nov. 15, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (NASDAQ: SGMO) announced today the presentation of positive data from the Phase 1 clinical trial of CERE-110 (AAV-NGF), a gene therapy approach designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease (AD). This novel product was developed by Ceregene,...

Researchers Uncover Mechanism For Improving Song Learning In Young Zebra Finches
2013-10-23 12:49:50

Max Planck Institute Most songbirds learn their songs from an adult model, mostly from the father. However, there are relatively large differences in the accuracy how these songs are copied. Researchers from the Max Planck Institute for Ornithology in Seewiesen now found in juvenile zebra finches a possible mechanism that is responsible for the differences in the intensity of song learning. They provided the nerve growth factor “BDNF” to the song control system in the brain. With this...

2013-08-26 16:24:50

Acquisition Provides Significant Portfolio of AAV Assets Including Manufacturing, Regulatory and Intellectual Property and a Fully Enrolled, Fully Funded Phase 2 trial in Alzheimer's Disease RICHMOND, Calif., Aug. 26, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that it signed a definitive agreement to acquire Ceregene, Inc., a privately held biotechnology company focused on developing adeno-associated virus (AAV) gene therapies. Sangamo will host a...

2013-03-13 08:30:50

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the completion of enrollment in its double-blind Phase 2 clinical study of CERE-110 (AAV-NGF), a gene therapy product designed to deliver nerve growth factor (NGF) for the treatment of Alzheimer's disease. The clinical study was carried out in collaboration with the Alzheimer's Disease Cooperative Study (ADCS) based at the University of California San Diego (UCSD) and funded by a grant from the National Institute on...

Semen Protein Prompts Ovulation
2012-08-21 09:17:20

John Neumann for redOrbit.com - Your Universe Online A brave team of researchers led by Canadian Gregg Adams from the University of Saskatchewan have discovered a protein in semen that acts on the brains of females prompting ovulation, and is the same molecule that regulates the growth, maintenance, and survival of nerve cells, reports e! Science News. The international team of researchers found that male mammals have accessory sex glands that contribute seminal fluid to semen, but the...

2012-07-31 12:27:31

During Alzheimer's disease, 'plaques' of amyloid beta (Ab) and tau protein 'tangles' develop in the brain, leading to the death of brain cells and disruption of chemical signaling between neurons. This leads to loss of memory, mood changes, and difficulties with reasoning. New research published in BioMed Central's open access journal Alzheimer's Research & Therapy, has found that up-regulating the gene Hes1 largely counteracted the effects of Ab on neurons, including preventing cell...

2012-03-09 02:14:48

New study points to possible new therapeutic approaches in treatment of AD A research group led by Dr. A. Claudio Cuello of McGill University's Faculty of Medicine, Dept. of Pharmacology and Therapeutics, has uncovered a critical process in understanding the degeneration of brain cells sensitive to Alzheimer's disease (AD). The study, published in the February issue of the Journal of Neuroscience, suggests that this discovery could help develop alternative AD therapies. A breakdown in...

2011-12-21 11:43:31

Diabetes is a major risk factor for cardiovascular disease and can reduce blood supply to the heart tissue and damage cardiac cells, resulting in heart failure. New research has investigated if nerve growth factor (NGF) gene therapy can prevent diabetic heart failure and small vascular disease in mice. The study by Professor Costanza Emanueli, British Heart Foundation Senior Research Fellow and colleagues of the Bristol Heart Institute in the Regenerative Medicine Section of the School of...

2011-02-09 06:30:00

RESEARCH TRIANGLE PARK, N.C., Feb. 9, 2011 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders. CXB909 is a small molecule, orally active agent that...

2010-04-20 08:42:55

Stanford University School of Medicine researchers have identified several small molecules that mimic a key but cumbersome protein in the brain, a discovery that could open the door to new therapies for a variety of brain disorders. The protein, designated by the acronym BDNF, is known to be involved in important brain functions that include memory and learning. "These small molecules could be the basis of drugs that provide entirely new avenues of treatment for a large number of...